Theriva Biologics special meeting fails due to no quorum; new meeting to seek warrant approval

Theriva Biologics, Inc.

Special meeting on Feb 11, 2026 could not convene because a quorum was not present.
Company will call a new meeting to seek approval to issue up to 16,184,560 shares upon warrant exercise.
Under Inducement Agreement dated Oct 16, 2025, must call meetings every 60 days until approval or warrants expire.
New meeting date and proxy materials to be announced later.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.